Alan B. Lancz & Associates, Inc. Abb Vie Inc. Transaction History
Alan B. Lancz & Associates, Inc.
- $98.1 Million
- Q2 2025
A detailed history of Alan B. Lancz & Associates, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Alan B. Lancz & Associates, Inc. holds 5,124 shares of ABBV stock, worth $1.19 Million. This represents 0.97% of its overall portfolio holdings.
Number of Shares
5,124
Previous 5,124
-0.0%
Holding current value
$1.19 Million
Previous $1.07 Million
11.37%
% of portfolio
0.97%
Previous 1.16%
Shares
8 transactions
Others Institutions Holding ABBV
# of Institutions
4,329Shares Held
1.3BCall Options Held
16.1MPut Options Held
10.9M-
Vanguard Group Inc Valley Forge, PA177MShares$41.1 Billion0.55% of portfolio
-
Black Rock Inc. New York, NY136MShares$31.7 Billion0.54% of portfolio
-
State Street Corp Boston, MA80MShares$18.6 Billion0.57% of portfolio
-
Jpmorgan Chase & CO New York, NY54.8MShares$12.7 Billion0.9% of portfolio
-
Morgan Stanley New York, NY41.7MShares$9.68 Billion0.52% of portfolio
About AbbVie Inc.
- Ticker ABBV
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,768,099,968
- Market Cap $410B
- Description
- AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...